CY 2027 ESRD PPS final rule: base rate, low-volume attestation and quality changes
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · High priority
CMS's calendar year (CY) 2027 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) final rule, Federal Register document 2026-22194, was published October 30, 2026 and takes effect January 1, 2027. It sets the unadjusted bundled payment base rate at $297.52 per treatment, up from $281.71 in 2026, and sets the CY 2027 base payment for dialysis furnished by ESRD facilities to beneficiaries with acute kidney injury (AKI) at $297.52 before the applicable geographic adjustment. For payment year 2027, an eligible facility seeking the low-volume payment adjustment (LVPA) must provide its attestation by December 31, 2026, the temporary pediatric ESRD add-on ends that day, and ESRD Quality Incentive Program (QIP) measure changes begin with payment year 2029.
Current status
The Federal Register record for document 2026-22194, retrieved on November 9, 2026 (Pacific time), still shows an effective date of January 1, 2027 and lists no corrections. Final technical specifications for the ESRD Quality Reporting System (EQRS) and any Medicare contractor instructions for the attestation were not checked.
Who this affects
ESRD facilities billing Medicare, including dialysis they furnish to beneficiaries with acute kidney injury (AKI).
Why it matters
CMS estimates that Medicare ESRD PPS payments across facilities will rise 2.7% in CY 2027 compared with estimated 2026 payments, an aggregate projection that is not a guarantee of the same increase for each provider or of an increase in all-payer revenue. Inference: an eligible facility seeking the low-volume adjustment that does not provide its attestation by December 31, 2026 should not expect the 2027 adjustment, so finance must finish eligibility and tier checks well before year end.
Required actions
- For payment year 2027, an eligible facility seeking the low-volume adjustment must provide its attestation by 2026-12-31 (conditional, not universal).
Recommended action
- Revenue-cycle and finance: model the rate and geographic adjustment against actual treatment mix; separately assess LVPA eligibility, ownership aggregation, cost-report history and tier; prepare the attestation before the deadline if seeking payment.
- Pharmacy, clinical and contracting: assess binder procurement, supply and transitions for eligible ESRD and AKI patients.
- Home-dialysis leaders: review training capacity, billing configuration and backup-support arrangements.
- Quality and laboratory: map the first pre-dialysis monthly phosphorus value into EQRS workflows, check continuity and exclusions, validate historical data.
- Track CMS and Medicare Administrative Contractor (MAC) implementation guidance; confirm existing requirements remain before discontinuing a prior QIP reporting process.
Implementation playbook
- Decide whether the facility is eligible for the CY 2027 low-volume adjustment and will seek it: check treatment counts, ownership aggregation, cost-report history and tier. Owner: Finance. Due: 2026-11-30.
- If seeking the adjustment, prepare the attestation and provide it by the rule's date. Owner: Finance and Revenue Cycle. Due: 2026-12-31 (the date stated for payment year 2027; applies only to an eligible facility seeking the adjustment).
- Model the CY 2027 base rate and geographic adjustment against the actual treatment mix and update the 2027 budget. Owner: Finance. Due: 2026-12-15.
- Plan for the end of the temporary pediatric add-on. Owner: Finance, with pediatric dialysis leadership. Due: 2026-12-31 (the add-on's end date).
- Assess binder procurement, supply and patient transitions for eligible ESRD and AKI patients. Owner: Pharmacy, Clinical Operations and Contracting. Due: 2026-12-15.
- Review home dialysis training capacity, billing configuration and backup-support arrangements. Owner: Home Dialysis leadership. Due: 2026-12-15.
- Map the first pre-dialysis monthly phosphorus value into the EQRS reporting workflow, check continuity and exclusions, and validate historical data. Owner: Quality and Laboratory. Due: 2026-12-31.
- Check for CMS and Medicare contractor implementation guidance, and confirm existing reporting requirements remain before stopping any current quality reporting process. Owner: Compliance. Due: 2026-12-01, then monthly.
Scope and timing
- Authority status
- Final
- Responsible owner
- Revenue Cycle and Finance (primary); affected: Pharmacy, Clinical Operations, Contracting, Home Dialysis, Quality, Laboratory
- Publication date
- 2026-10-30
- Effective date
- 2027-01-01
- Compliance date
- 2026-12-31 (low-volume adjustment attestation, eligible facilities seeking the adjustment)
- Other dates
- Temporary pediatric ESRD add-on ends 2026-12-31; QIP changes begin with payment year 2029
Not established
The playbook's due dates are planning dates set by this briefing, apart from the December 31, 2026 dates stated for the attestation and the pediatric add-on. Final EQRS technical specifications and any Medicare contractor instructions for the attestation were not checked. Quality program changes begin with payment year 2029.
Earlier article: November 4, 2026 edition →
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Medicare & Medicaid Sweep report →